F11 and stage 5 chronic kidney disease: Currently, FXI inhibitors are being investigated in various clinical settings, including total knee arthroplasty, atrial fibrillation, non-cardioembolic stroke, end-stage renal disease, myocardial infarction, coronavirus disease 2019, and cancer-associated VTE [39].